Tagged with Merck,

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Germany A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’ withdrawal from purchase of Evotec; Merck KGaA-controlled MilliporeSigma’s acquisition of HUB Organoids, and Gilead’s USD 465 million solid tumour deal…

China While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life sciences ecosystem. Eased restrictions on foreign investment have made it even more attractive for international pharma while China’s native innovators…

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Switzerland Switzerland’s healthcare system is globally renowned. It leads the world on metrics such as infrastructure, medical advances, and patient freedom to choose healthcare services, and ranks 1st in US thinktank FREOPP’s 2022 World Index of Healthcare Innovation. However, it lags in one key area: digitalisation. On that front, Switzerland has…

China Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses Merck’s long-term commitment to China, highlighting the company’s 91 years of operations in the country, diverse portfolio, strong emphasis on…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

China An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue decline, and Aditum Bio and Leads Biolabs’ creation of autoimmune disease-focused Oblenio Bio. AstraZeneca’s China chief in custody, believes unrelated…

Germany The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space with Google DeepMind; and the recipe to fix the country’s ailing healthcare system.   Germany’s Merck open to more M&A…

Switzerland Florian Schick of Merck Switzerland reflects on his career journey and the unique challenges and opportunities within the Swiss healthcare landscape. He highlights Merck’s commitment to innovation the importance of collaboration to drive positive change in the industry and what’s needed to tackle infertility in Switzerland.   Switzerland has all…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

China A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese approval of AstraZeneca and Daiichi Sankyo’s gastric cancer therapy.   China’s BeiGene opens new clinical R&D and biologics manufacturing facility…